• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 15, 2015

View Archived Issues

Raptor Pharmaceutical rapped after RP103 disappoints in pediatric NASH

Raptor Pharmaceutical Corp.'s program to advance RP103 (cysteamine bitartrate delayed-release) in pediatric nonalcoholic steatohepatitis (NASH) "has always been a little bit left of center," president and CEO Julie Anne Smith maintained Monday. "Our core competency is in rare diseases. Read More

In the clinic

Lion Biotechnologies Inc., of New York, said it opened enrollment in a phase II trial of lead candidate LN-144 for the treatment of refractory metastatic melanoma. Read More

Other news to note

Kite Pharma Inc., of Santa Monica, Calif., said it expanded its agreement with the Netherlands Cancer Institute (NKI). Kite will receive an exclusive option to license a number of T-cell receptor gene sequences to develop and commercialize cancer immunotherapy candidates targeting solid tumors. Read More

Acacia Pharma seeks to bring in whopping $231M for LSE IPO

LONDON – Acacia Pharma Ltd. will go public on the London Stock Exchange with the aim of raising £150 million (US$231 million) to complete development and begin commercialization of its two lead products for treating postoperative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Read More

Smac mimetics help HDAC inhibitors roust HIV

Researchers have identified smac mimetics as a class of cancer drugs that synergized with histone deacetylase (HDAC) inhibitors to flush HIV out of hiding in infected T cells. The results suggest that smac mimetics could help achieve one of the major goals of current HIV research – an eradication cure. Read More

Major players departing pharma for newer firms

BOSTON – Biopharm America, designed to spur strategic relationships by way of a web-based service that sets up face-to-face meetings and more, kicks off today with 457 companies, 686 delegates, and 771 licensing opportunities on the roster as of last Friday. Read More

Investors 'ZEALous' as Sanofi phase III data keep Lixilan filing on track

DUBLIN – Sanofi SA remains on track to complete a fourth-quarter regulatory submission of Lixilan, a fixed-ratio combination of its basal insulin (Lantus; insulin glargine) and its glucagon-like peptide 1 (GLP-1) receptor agonist Lyxumia (lixisenatide), on the back of a positive readout from the second of two phase III trials in type 2 diabetes patients. Read More

Latin America + MENA countries = opportunities, but with challenges

BOGOTA, Colombia – The links between the biotech sectors in Latin America and the Middle East and North Africa (MENA) remain shallow, even if industry stakeholders in both sides believe in the potential the relationships represent. Read More

Regulatory front

The FDA will begin exercising its authority next month to destroy drugs valued at $2,500 or less that have been refused admission into the U.S. under the Federal Food, Drug and Cosmetic Act. Read More

Stock movers

Read More

Financings

Dimension Therapeutics Inc., of Cambridge, Mass., has filed to raise up to $115 million in an IPO. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe